{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:25:34Z","timestamp":1747977934354,"version":"3.41.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clml.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:27:34Z","timestamp":1736814454000},"page":"e366-e373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey V.","family":"Danilov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Barrientos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayder","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clml.2025.01.005_bib0001","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.3390\/cancers13205181","article-title":"Cellular therapy updates in B-cell lymphoma: the State of the CAR-T","volume":"13","author":"Crees","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.01.005_bib0002","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41408-023-00902-x","article-title":"Zanubrutinib: past, present, and future","volume":"13","author":"Tam","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.01.005_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221080743","article-title":"Mantle cell lymphoma management trends and novel agents: where are we going?","volume":"13","author":"Pu","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2025.01.005_bib0004","first-page":"1","article-title":"New directions for mantle cell lymphoma in 2022","volume":"42","author":"Kumar","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.clml.2025.01.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.clml.2025.01.005_bib0006","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2025.01.005_bib0007","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1182\/bloodadvances.2023011271","article-title":"Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma","volume":"7","author":"Karmali","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2025.01.005_bib0008","first-page":"1269","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","volume":"109","author":"Song","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2025.01.005_bib0009","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0011","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.005_bib0012","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.005_bib0013","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0014","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023012424","article-title":"Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis","volume":"8","author":"Wang","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.005_bib0015","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-risk mantle cell lymphoma: definition, current challenges, and management","volume":"38","author":"Jain","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0016","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene Maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.01.005_bib0017","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2023-180069","article-title":"A multicenter phase 2 trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in patients with treatment-na\u00efve, TP53-Mutant Mantle Cell Lymphoma","volume":"142","author":"Kumar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.005_bib0018","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1182\/bloodadvances.2023009992","article-title":"Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma","volume":"7","author":"Phillips","year":"2023","journal-title":"Blood Adv"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.01.005_bib0019","article-title":"Long term follow-up of untreated\/relapsing MCL patients with the ibrutinib, obinotuzumab, and venetoclax combination","volume":"7","author":"Le Gouill","year":"2023","journal-title":"Hemasphere"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.01.005_bib0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2022-158656","article-title":"Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-na\u00efve mantle cell lymphoma","volume":"140","author":"Ruan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.005_bib0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00428-022-03460-y","article-title":"Chronic lymphocytic leukaemia\/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation","volume":"482","author":"Sander","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clml.2025.01.005_bib0022","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","article-title":"Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions","volume":"131","author":"Puente","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.005_bib0023","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2025.01.005_bib0024","unstructured":"NCCN. Clinical Practice Guidelines in Oncology. Chronic lymphocyctic leukemia\/small lymphocytic lymphoma, version 1. 2025. Accessed January 3, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf."},{"key":"10.1016\/j.clml.2025.01.005_bib0025","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.01.005_bib0026","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration Ibrutinib plus Venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.01.005_bib0027","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration Ibrutinib plus Venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.01.005_bib0028","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.005_bib0029","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.01.005_bib0030","article-title":"Zanubrutinib (Zanu) vs bendamustine + rituximab (BR) in patients (Pts) with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): extended follow-up of the SEQUOIA study","volume":"7","author":"Munir","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.01.005_bib0031","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0032","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.01.005_bib0033","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.005_bib0034","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration Ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clml.2025.01.005_bib0036","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.2022015560","article-title":"Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse","volume":"140","author":"Rusconi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.005_bib0037","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/neurolint14010009","article-title":"Ibrutinib in refractory or relapsing primary Central nervous system lymphoma: a systematic review","volume":"14","author":"Nepal","year":"2022","journal-title":"Neurol Int"},{"key":"10.1016\/j.clml.2025.01.005_bib0038","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.005_bib0039","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000534730","article-title":"Frontline therapy in chronic lymphocytic leukemia","volume":"147","author":"Arguello-Tomas","year":"2024","journal-title":"Acta Haematol"},{"issue":"13","key":"10.1016\/j.clml.2025.01.005_bib0040","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.01.005_bib0041","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"31","key":"10.1016\/j.clml.2025.01.005_bib0042","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.01.005_bib0043","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clml.2022.09.007","article-title":"Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: a real-world database study","volume":"23","author":"Mato","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.01.005_bib0044","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1182\/blood-2023-187129","article-title":"Clinical outcomes in patients treated with both covalent BTKis and venetoclax and the significance of \u201cdouble-refractory\u201d status in patients with CLL\/SLL","volume":"142","author":"Samples","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.005_bib0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.005_bib0046","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0047","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.01.005_bib0048","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood-2023-178623","article-title":"Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.005_bib0049","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from Polatuzumab Vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.005_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1168622","article-title":"T-cell redirecting therapies for B-cell non-hodgkin lymphoma: recent progress and future directions","volume":"13","author":"Russler-Germain","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0051","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.005_bib0052","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.005_bib0053","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2023.2285978","article-title":"Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma","volume":"16","author":"Davis","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2025.01.005_bib0054","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.005_bib0055","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.005_bib0056","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1002\/hem3.62","article-title":"Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy","volume":"8","author":"Iacoboni","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.01.005_bib0057","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1182\/bloodadvances.2022009066","article-title":"The race is on: bispecifics vs CAR T cells in B-cell lymphoma","volume":"7","author":"Gurumurthi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.005_bib0058","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.seminhematol.2023.11.007","article-title":"CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: why does it fail?","volume":"60","author":"Kinoshita","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2025.01.005_bib0059","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2025.01.005_bib0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T01:21:32Z","timestamp":1747963292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2152265025000163"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}